|Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes|
ADVANCE Collaborative Group
New England journal of medicine 358 (24), 2560-2572, 2008
|Canagliflozin and renal outcomes in type 2 diabetes and nephropathy|
V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ...
New England Journal of Medicine 380 (24), 2295-2306, 2019
|A randomized, controlled trial of early versus late initiation of dialysis|
BA Cooper, P Branley, L Bulfone, JF Collins, JC Craig, MB Fraenkel, ...
New England Journal of Medicine 363 (7), 609-619, 2010
|Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy|
A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ...
The Lancet 390 (10105), 1888-1917, 2017
|The influence of dialysis treatment modality on the decline of remaining renal function.|
MJ Lysaght, EF Vonesh, F Gotch, L Ibels, M Keen, B Lindholm, KD Nolph, ...
ASAIO transactions 37 (4), 598-604, 1991
|Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease|
Sharp Collaborative Group
American heart journal 160 (5), 785-794. e10, 2010
|Glucose handling by the kidney|
A Mather, C Pollock
Kidney international 79, S1-S6, 2011
|Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial|
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
|Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?|
U Panchapakesan, K Pegg, S Gross, MG Komala, H Mudaliar, J Forbes, ...
PloS one 8 (2), e54442, 2013
|Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis|
ISPD Adequacy of Peritoneal Dialysis Working Group
Peritoneal Dialysis International 26 (5), 520-522, 2006
|Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results …|
KW Mahaffey, MJ Jardine, S Bompoint, CP Cannon, B Neal, ...
Circulation 140 (9), 739-750, 2019
|Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD|
BA Cooper, EL Penne, LH Bartlett, CA Pollock
American Journal of Kidney Diseases 43 (1), 61-66, 2004
|Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference|
IC Macdougall, AJ Bircher, KU Eckardt, GT Obrador, CA Pollock, ...
Kidney international 89 (1), 28-39, 2016
|Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey|
N Evangelidis, A Tong, B Manns, B Hemmelgarn, DC Wheeler, P Tugwell, ...
American Journal of Kidney Diseases 70 (4), 464-475, 2017
|Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference|
CT Chan, PJ Blankestijn, LM Dember, M Gallieni, DCH Harris, CE Lok, ...
Kidney international 96 (1), 37-47, 2019
|The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics|
MJ Jardine, KW Mahaffey, B Neal, R Agarwal, GL Bakris, BM Brenner, ...
American journal of nephrology 46 (6), 462-472, 2017
|Validity of subjective global assessment as a nutritional marker in end-stage renal disease|
BA Cooper, LH Bartlett, A Aslani, BJ Allen, LS Ibels, CA Pollock
American journal of kidney diseases 40 (1), 126-132, 2002
|Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells|
SC Jones, HJ Saunders, W Qi, CA Pollock
Diabetologia 42, 1113-1119, 1999
|Comparing different methods of assessing body composition in end-stage renal failure|
BA Cooper, A Aslani, M Ryan, FYP Zhu, LS Ibels, BJ Allen, CA Pollock
Kidney international 58 (1), 408-416, 2000
|Integrated actions of transforming growth factor-β1 and connective tissue growth factor in renal fibrosis|
W Qi, S Twigg, X Chen, TS Polhill, P Poronnik, RE Gilbert, CA Pollock
American Journal of Physiology-Renal Physiology 288 (4), F800-F809, 2005